Hugel Achieves Exceptional Financial Milestone in 2025
Hugel Inc., a prominent player in the global medical aesthetics sector, has announced its financial results for 2025, showcasing extraordinary growth. The company reported net sales of KRW425.1 billion and an operating profit of KRW201.6 billion, reflecting increases of 14% and 21.3% compared to the previous year.
Impressive Growth in Product Sales
The driving force behind Hugel's remarkable performance was the heightened demand for its flagship products, including the botulinum toxin Botulax, known as Letybo, and its acclaimed hyaluronic acid dermal fillers, THE CHAEUM and BYRYZN. Additionally, Hugel experienced rapid advancements in its cosmetic offerings, comprising WELLAGE and BYRYZN BR, further contributing to the sales surge.
Among its product lines, sales from toxin products amounted to KRW233.8 billion, while the dermal fillers brought in KRW129.7 billion. The combined revenue from cosmetics and miscellaneous items reached KRW61.6 billion, highlighting the diverse portfolio of Hugel's offerings.
Export Growth and International Expansion
Notably, the company achieved a significant milestone with 74% of its toxin and dermal filler product sales generated from exports, a sharp increase from 66% in 2024. The total international sales for the year climbed to KRW268.5 billion, representing an impressive growth of 22% year-on-year.
Particularly strong growth was noted in the Americas, specifically in the US and Brazil. There, combined sales for toxin and dermal filler products soared by 105% over the prior year, culminating in total sales of KRW67.9 billion. In the final quarter, sales for the region witnessed a staggering increase of nearly 310%, indicating robust market demand.
Strategic Growth Initiatives
Hugel aims to amplify its global presence further. The company is set to implement a hybrid sales strategy this coming year, blending partner distribution with direct sales efforts, particularly focusing on the US, which is recognized as the largest market for botulinum toxin.
According to Carrie Strom, Hugel’s President and Global CEO, the company is committed to sustaining its competitive edge and consolidating its growth trajectory. "Surpassing KRW400 billion in annual net sales is a monumental achievement for us,” she stated, emphasizing their focus on expanding into the world’s Big 4 markets, which include the US, China, Europe, and Brazil.
Financial Highlights for the Fourth Quarter
Reflecting the overall year’s success, Hugel reported an increase of 21.3% in net sales and a 26.2% rise in operating profit in the fourth quarter, totaling KRW119.1 billion and KRW58.6 billion, respectively. These figures reinforce Hugel's strong market position as they continue to push for expansion and innovation.
About Hugel
Founded in 2001, Hugel has established itself as a leader in the medical aesthetics field. The company specializes in creating injectables designed for skin rejuvenation, including botulinum toxins and hyaluronic acid fillers, alongside a range of skin boosters and absorbable sutures.
Over the last twenty years, Hugel's commitment to safety and quality has solidified its reputation. With operations in nearly seventy countries and nine subsidiaries worldwide, including markets in the US, Australia, and Asia, the company enjoys a robust foundation for future growth. Hugel has an unwavering commitment to enhancing industry standards through rigorous medical affairs, extensive training, and active participation in industry forums.
Hugel remains poised to exploit its competitive advantages, leveraging strong market dynamics to maintain and accelerate its growth trajectory internationally.
Frequently Asked Questions
What are the main products of Hugel?
Hugel specializes in botulinum toxins, hyaluronic acid dermal fillers, and cosmetic products.
What were Hugel's financial results for 2025?
The company reported record-high net sales of KRW425.1 billion and operating profit of KRW201.6 billion.
How did sales in the Americas perform?
Sales in the Americas surged by 105% year-on-year, reaching KRW67.9 billion.
What is Hugel's growth strategy for the US market?
Hugel plans to use a hybrid sales model that combines partner distribution with direct sales to capture more market share in the US.
When was Hugel founded?
Hugel was established in 2001, and has since grown into a leading company in the medical aesthetics sector.
